Prediabetes: A Fundamental Text begins with an overview of the demographic, anthropometric, biobehavioral, and biochemical factors that drive the transition from normal blood glucose to prediabetes. Emerging knowledge from the fi elds of genomics, transcriptomics, microRNAs, metabolomics, and microbiomics is incorporated into a comprehensive treatise on the pathobiology of prediabetes.
The focus then shifts to evidence-based management of prediabetes and prevention of type 2 diabetes. Emphasis is placed on practical adaptations that would enable cost effective community diabetes prevention initiatives.
Interventions utilizing lifestyle modification are prioritized over medications, but novel approaches (including cyclical medication strategy, designer nutraceuticals, and metabolic surgery) are also discussed.
The deep understanding offered by Prediabetes: A Fundamental Text is critical to the discovery and delivery of programs for preventing diabetes, and is an essential resource for clinicians, researchers, public health practitioners, and policy makers.
"Disclosures", Prediabetes: A Fundamental text. Pathophysiology, Complications, Management, Reversal, Sam Dagogo-Jack, MD, DSc
Download citation file:
Dr. Dagogo-Jack has served as a principal investigator or co-investigator for clinical trial contracts between the University of Tennessee and AstraZeneca, Novo Nordisk, and Boehringer-Ingelheim; has served as a consultant and advisory board member for AstraZeneca, Bayer, Boehringer-Ingelheim, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi; and holds equity interests in Jana Care, Inc., and Aerami Therapeutics. He has also served as an expert for Sidley Austin, Adam and Reese, and Wheeler Trigg O’Donnell law firms on litigation related to diabetes and hormonal disorders.
